1. Simon R. Baysian design and analysis of active control clinical trials. Biometrics., 1999;55:484–487.
2. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm., 1987;15:657–680.
3. Food and Drug Administration. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products—general considerations. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; October 2000.
4. International Conference on Harmonization; E-9 Document; Guidance on Statistical Principles for Clinical Trials. Federal Register. 1998; Vol. 63, 179:49583–49598.
5. International Conference on Harmonization; E-10 Document; Choice of Control Group in Clinical Trials. Federal Register. 1999; Vol. 64, 185:51767–51780.